CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Desogen (ethinyl estradiol and desogestrel) +1 moredrug
Likely dose
Desogen (ethinyl estradiol and desogestrel) 0.15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00612508
NCT00612508N/ACompleted
CompareCT.gov

The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health

Oregon Health and Science University·interventional·Posted Feb 11, 2008·Updated Nov 8, 2012

In Brief

A clinical study evaluating Desogen (ethinyl estradiol and desogestrel) and NuvaRing (ethinyl estradiol and etonogestrel) for Contraceptive Usage and Vaginal Epithelial Disruption. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraceptive Usage, Vaginal Epithelial Disruption
CountriesUnited States
CollaboratorsOregon Clinical and Translational Research Institute

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2008
Enrollment StartMay 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.4 years ago

Interventions

Desogen (ethinyl estradiol and desogestrel)drug

1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol

NuvaRing (ethinyl estradiol and etonogestrel)drug

Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring